Becton, Dickinson and Co. (BD) closed enrollment of its Lutonix 014 drug coated balloon (DCB) trial for treatment of patients with critical limb ischemia (CLI) and claudication due to below-the-knee (BTK) stenotic or occluded arterial lesions. Research is intended to support premarket approval, which the firm is expected to apply for late this year. Lutonix was initially developed under C.R. Bard Inc., which was acquired by BD in 2017. Read More
